At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 725 enrolled
Drug / intervention
AZD7325 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of AZD7325 in the Treatment of Generalized Anxiety Disorder (GAD)
In Brief
A Phase 2 clinical trial evaluating AZD7325 and Placebo for Anxiety Disorders. Completed, enrolled 725 participants across 52 sites.
Detailed Summary
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedDec 2008
Primary CompletionMay 2009
TodayJul 2026
First PostedDec 15, 2008
Enrollment StartDec 1, 2008
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.5 years ago
Interventions
AZD7325drug
2 tablets taken twice a day for 28 days
AZD7325drug
2 tablets taken twice a day for 28 days
AZD7325drug
2 tablets taken twice a day for 28 days
Placebodrug
2 tablets taken twice a day for 28 days